New drug BHB810 aims to control advanced stomach cancer
NCT ID NCT07529808
First seen Apr 14, 2026 · Last updated May 03, 2026 · Updated 2 times
Summary
This study tests a new drug called BHB810 in adults with advanced stomach or gastroesophageal junction cancer that has not responded to other treatments. The drug is given as an IV infusion every two weeks. The goal is to see if it is safe and can help shrink or control the cancer. About 164 people will take part.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC CANCER are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.